Study #2014-0930
Combination of Nivolumab and Ipilimumab with 5-azacitidine in Patients with Myelodysplastic Syndromes (MDS)
MD Anderson Study Status
Not Accepting
Treatment Agent
Nivolumab, Ipilimumab, Azacitidine
Description
This phase II trial studies the side effects of nivolumab and/or ipilimumab with or without azacitidine and to see how well they work in treating patients with myelodysplastic syndrome. Monoclonal antibodies, such as nivolumab and ipilimumab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and/or ipilimumab with or without azacitidine may work better in treating myelodysplastic syndrome.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Leukemia, Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome
Study phase:
Phase II
Physician name:
Guillermo Garcia-Manero
Department:
Leukemia
For general questions about clinical trials:
1-844-929-4217
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.